Agios Pharmaceuticals moved to expand its oncology pipeline with a potentially $665 million deal for Oscotec’s cevidoplenib. The transaction grants Agios exclusive global rights to develop and commercialize the oral SYK inhibitor for immune thrombocytopenia, positioned as phase III-ready. The agreement includes $25 million up front, up to $140 million in development and regulatory milestones across as many as three indications in the US and Europe, and royalties in the high single-digit to mid-teens range. Oscotec could also earn up to $500 million in commercial milestones for future net sales. For investors and competitors, the deal signals continued focus on resistance-linked oncology pathways and the willingness of larger biopharmas to buy late-stage-ready assets when clinical differentiation is supported by early data.